Targeting CK2 for cancer therapy using a nanomedicine approach

Khalil Ahmed, Gretchen Unger, Betsy T. Kren, Janeen H. Trembley

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Scopus citations


CK2 is a signal-responsive serine/threonine protein kinase which promotes cell proliferation, suppresses apoptosis, and demonstrates increased expression in numerous cancers. Here, we present information on investigations into CK2-focused cancer therapy in general and discuss in detail a nanomedicine approach to targeting CK2 in a cancer cell-specific manner. Specifically, we summarize data on biodistribution and therapeutic efficacy of a tenfibgen (TBG) nanoencapsulation technology for the delivery of anti-CK2 cargos to malignant cells. The TBG nanocapsule cargos discussed include siRNA (siCK2), single-stranded DNA/RNA chimeric oligonucleotides (RNAi-CK2), and a small-molecule CK2 inhibitor (DMAT). Systemic administration of TBG-RNAi-CK2 resulted in xenograft tumor reduction using low doses with concomitant reduction in CK2 protein expression. Systemic TBG-DMAT treatment decreased xenograft tumor proliferation. No toxicity or early inflammation response was observed after using any of the TBG encapsulated anti-CK2 cargos. The utility of this therapy approach for targeting metastatic cancer sites and on overall survival is also discussed. Protected and malignant cell-specific delivery of a therapeutic is a promising target-specific and versatile approach for cancer therapy, and both the TBG encapsulation technology and the anti-CK2 oligonucleotide approach demonstrate substantial potential for the treatment of malignancy.

Original languageEnglish (US)
Title of host publicationProtein Kinase CK2 Cellular Function in Normal and Disease States
PublisherSpringer International Publishing
Number of pages17
ISBN (Electronic)9783319145440
ISBN (Print)9783319145433
StatePublished - Jan 1 2015


  • Antisense
  • Biodistribution
  • CK2
  • DMAT
  • Metastasis
  • Nanocapsule
  • Nanomedicine
  • Nanoparticle
  • Prostate
  • RNAi
  • SiRNA
  • Xenograft


Dive into the research topics of 'Targeting CK2 for cancer therapy using a nanomedicine approach'. Together they form a unique fingerprint.

Cite this